Cosela™ (trilaciclib) – New drug approval
February 12, 2021 - The FDA announced the approval of G1 Therapeutics’ Cosela (trilaciclib), to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).
Top